Enhanced comprehension of the comorbidity landscape within the T2DM population enables the identification of more defined study cohorts for novel therapies, such as GLP-1 receptor agonists (GLP-1 RAs) and sodium-glucose co-transporter-2 (SGLT2) inhibitors. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.